The latest market intelligence report published by Vietcap Securities indicates that Vietnam’s retail pharmacy landscape is undergoing an aggressive consolidation phase, tracking toward an oligopolistic market structure. Within this structural transition, modern pharmacy chains are systematically capturing substantial market share from legacy, fragmented traditional mom-and-pop drugstores, fundamentally reshaping the country’s pharmaceutical commerce.
The documented VND 214,000 billion market valuation, Long Chau’s aggressive ascent to a 25% market share, and the post-restructuring, capital-fueled expansion roadmaps of Pharmacity and An Khang feature:
-
Macro Horizons of a VND 214 Trillion Market and Fiscal Enforcement Drivers:
-
Market Scale: Third-party research verified that the aggregate valuation of Vietnam’s pharmaceutical market (excluding vaccines) reached approximately VND 214 trillion in 2025, registering a robust compound annual growth rate (CAGR) of 10% across the 2020 – 2025 fiscal timeline.
-
Penetration Rates: Despite the massive scale, the penetration rate of organized modern retail pharmacy models remained conservative at just 19% in 2025. This baseline leaves immense commercial headroom for modern corporate chains to expand their footprints.
-
Regulatory Catalysts: Vietcap emphasizes that the state’s tightening of tax administration and the enforcement of strict transaction reporting mandates on individual business households serve as primary structural drivers accelerating the consumer migration away from traditional storefronts into modern managed chains.
-
-
Long Chau’s Absolute Market Leadership and Scale Dynamics:
-
Market Share Consolidation: Long Chau (a subsidiary of FPT Retail) has cemented its position as the definitive industry leader, emerging as the primary beneficiary of this sectoral consolidation. Vietcap estimates that Long Chau’s retail market share expanded from a mere 5% in 2021 to an unprecedented 25% in 2025, completely outstripping peer modern competitors.
-
Financial Metrics: This exponential growth trajectory was propelled by a phenomenal revenue CAGR of 72% paired with a store network CAGR of 57% over the 2021 – 2025 period. Simultaneously, Long Chau successfully optimized its operational leverage, lifting net profit margins from a break-even baseline in 2021 to approximately 2.1% in 2025.
-
-
Strategic Pivots and Post-Restructuring Capital Deployments by Pharmacity and An Khang:
-
Pharmacity Secures Foreign Private Equity: Following a multi-year turnaround program initiated in early 2023 focused on store rationalization and product assortment optimization, Pharmacity officially achieved positive EBITDA in the fourth quarter of 2025. The corporation recently closed a successful $50 million – $80 million funding round backed by private equity firm LeapFrog Investments. The fresh capital injection will bankroll aggressive store expansion into Tier-2 and Tier-3 municipalities, targeting a footprint of 2,000 stores by 2030 (nearly doubling its current network size).
-
An Khang Nears Operating Profitability: An Khang (under Mobile World Group) has approached its operational break-even threshold in the first quarter of 2026. This turnaround follows a rigorous restructuring framework launched in early 2024 aimed at refining store-level unit economics. An Khang’s executive board plans to roll out approximately 100 new stores, guiding the chain to achieve net profitability within the 2026 fiscal year.
-